TrialJournal for immunotherapy of cancer2021

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Davide Melisi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.